Search Results

Pictured: Novavax/Getty Images, STR/NurPhoto

FDA

UPDATE: FDA Lifts Clinical Hold on Novavax’s COVID/Flu Vaccine Candidates, Clears Phase III Trial

Novavax’s shared jumped 12% in pre-market trading on the news.

November 11, 2024

·

2 min read

·

Annalee Armstrong

Healthcare worker administers a vaccine to a patient

COVID-19

Novavax Catches Up to Competitors With FDA Approval for Updated COVID-19 Boosters

Unlike Pfizer/BioNTech and Moderna, Novavax does not use mRNA technology for its COVID-19 vaccine, instead opting for a recombinant version of the virus’ spike protein to elicit protection.

September 3, 2024

·

2 min read

·

Tristan Manalac

BioCapital

Novavax to Participate in 2024 Jefferies Global Healthcare Conference

Novavax, Inc. today announced it will participate in the 2024 Jefferies Global Healthcare Conference.

May 30, 2024

·

1 min read

Press Releases

Novavax Reports Third Quarter 2024 Financial Results and Operational Highlights

November 13, 2024

·

14 min read

Press Releases

Novavax Announces Grant of Inducement Awards Pursuant to Nasdaq Listing Rule 5635(c)(4)

November 15, 2024

·

2 min read

BioCapital

Novavax to Participate in BofA Securities 2024 Health Care Conference

Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will participate in the BofA Securities 2024 Health Care Conference.

May 13, 2024

·

1 min read

Novavax Soars on $1.4B Deal With Sanofi for COVID Vaccine

Sanofi will hand Novavax $500 million upfront for its COVID-19 vaccine, which it will co-commercialize and develop into a combination flu-COVID vaccine.

May 10, 2024

·

1 min read

·

Kate Goodwin

Business

Novavax Reports First Quarter 2024 Financial Results and Operational Highlights

Novavax, Inc., a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, announced its financial results and operational highlights for the first quarter ended March 31, 2024.

May 10, 2024

·

16 min read

Business

Novavax to Participate in Upcoming September Conferences

September 4, 2024

·

2 min read

BioCapital

Novavax Submits Application to European Medicines Agency for Updated Protein-based 2024-2025 Formula COVID-19 Vaccine

Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that it has filed for a type II variation of existing Marketing Authorization with the European Medicines Agency (EMA) for its JN.1 COVID-19 vaccine (NVX-CoV2705) for individuals aged 12 and older.

June 24, 2024

·

6 min read